AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

PRESS RELEASEAB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION ...

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

PRESS RELEASEAB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHAREParis, December ...
TipRanks on MSN

AB Science granted U.S. patnet for masitinib in treatment of SCD

AB Science (ABSCF) announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using ...
Yahoo Finance

AB Science will publish its 2024 annual financial report on May 9, 2025

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...
Yahoo Finance

AB Science will participate in the Biomed Forum investors conference

AB Science SA (Euronext – FR0010557264 – AB) announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by ...
manilatimes

AB Science today provides an update on its masitinib platform

AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its masitinib platform. The webcast presentation is available on the company's website, in ...
Morningstar

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
Hosted on MSN

AB Science Reports Key Developments and Financial Results

Ab Science ( (ABSCF)) has released its Q2 earnings. Here is a breakdown of the information Ab Science presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...
FierceBiotech

Analysts lay into AB Science after regulatory misstep

Analysts have torn into AB Science over the clinical trial compliance failings identified by regulators in France. Oddo took the most extreme action by slashing its price target from €48 ($53) to €5, ...
FierceBiotech

AB Science trumpets phase 3 ALS data, but investors seem unmoved

After years of disappointment, things might seem to be looking up for the amyotrophic lateral sclerosis patient community. Two weeks ago they got a new drug approved by the FDA, and now French biotech ...
Morningstar

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

AB Science SA (Euronext - FR0010557264 - AB) today announced the approval of the third of four stages of the Phase I/II study (AB18001) with the compound AB8939 in adult patients with ...
manilatimes

AB Science reports its revenues for the year 2024 and provides an update on its activities

Update on the AB8939 microtubule program and in particular on the ability of AB8939 to generate a response on MECOM rearrangement AB Science provided an update on the microtubule program AB8939.